VOTRIENT 400 MG Iżrael - Ingliż - Ministry of Health

votrient 400 mg

novartis israel ltd - pazopanib as hydrochloride - film coated tablets - pazopanib as hydrochloride 400 mg - pazopanib - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

MAYZENT 0.25 MG Iżrael - Ingliż - Ministry of Health

mayzent 0.25 mg

novartis israel ltd - siponimod as fumaric acid - film coated tablets - siponimod as fumaric acid 0.25 mg - siponimod - mayzent is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include relapsing-remitting disease, and active secondary progressive disease, in adults.

SIMULECT  20 MG Iżrael - Ingliż - Ministry of Health

simulect 20 mg

novartis israel ltd - basiliximab - powder and solvent for solution for injection/infusion - basiliximab 20 mg/vial - basiliximab - basiliximab - prophylaxis of acute organ rejection in de novo renal transplantation in combination with cyclosporin and corticosteroid based immunosuppression

OMNITROPE 10 MG1.5 ML Iżrael - Ingliż - Ministry of Health

omnitrope 10 mg1.5 ml

novartis israel ltd - somatropin recombinant - solution for injection - somatropin recombinant 10 mg / 1.5 ml - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (height sds<2.5 and parenteral adjusted height sds < -1) in short children born sga (sga - small for gestational age i.e. born small in relation to the length of the fetus development) with a birth weight and/or length < 2 sd who failed to show catch up growth (hv sds < 0 during the last year) by 4 years of age or later. prader willi syndrome (pws) for improvement of growth and body composition. adults: for adults who have suffered from growth-hormone deficiency since childhood. for adults who have acquired growth hormone deficiency due to a pituitary pathology causing hypopituitarism.

OMNITROPE 15 MG1.5 ML Iżrael - Ingliż - Ministry of Health

omnitrope 15 mg1.5 ml

novartis israel ltd - somatropin recombinant - solution for injection - somatropin recombinant 15 mg / 1.5 ml - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (height sds<2.5 and parenteral adjusted height sds < -1) in short children born sga (sga - small for gestational age i.e. born small in relation to the length of the fetus development) with a birth weight and/or length < 2 sd who failed to show catch up growth (hv sds < 0 during the last year) by 4 years of age or later. prader willi syndrome (pws) for improvement of growth and body composition. adults: for adults who have suffered from growth-hormone deficiency since childhood. for adults who have acquired growth hormone deficiency due to a pituitary pathology causing hypopituitarism.

KISQALI 200 MG Iżrael - Ingliż - Ministry of Health

kisqali 200 mg

novartis israel ltd - ribociclib as succinate - film coated tablets - ribociclib as succinate 200 mg - ribociclib - kisqali is indicated in combination with:* a non-steroid aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer, as initial endocrine-based therapy.or* fulvestrant for the treatment of men and postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.

TOBREX 2X Iżrael - Ingliż - Ministry of Health

tobrex 2x

novartis israel ltd - tobramycin - eye drops - tobramycin 0.3 % - tobramycin - tobramycin - antibiotic for the treatment of superficial eye infections caused by bacteria sensitive to tobramycin.

CATAFLAM 50 MG Iżrael - Ingliż - Ministry of Health

cataflam 50 mg

novartis israel ltd - diclofenac as potassium - tablets - diclofenac as potassium 50 mg - diclofenac - diclofenac - management of pain and primary dysmenorrhea, when prompt pain relief is desired.

LUCENTIS Iżrael - Ingliż - Ministry of Health

lucentis

novartis israel ltd - ranibizumab - solution for injection - ranibizumab 10 mg/ml - ranibizumab - ranibizumab - treatment of patients with neovascular (wet) age-related macular degeneration (amd). treatment of adult patients with visual impairment due to diabetic macular oedema (dme) . the treatment of visual impairement due to macular oedema secondary to retinal vein occlusion (rvo). the treatment of visual impaiment due to choroidal neovascularization (cnv) . lucentis is indicated in preterm infants for: the treatment of retinopathy of prematurity (rop) with zone i (stage 1+, 2+, 3 or 3+), zone ii (stage 3+) or ap-rop (aggressive posterior rop) disease.the treatment of proliferative diabetic retinopathy (pdr)

HYCAMTIN IV Iżrael - Ingliż - Ministry of Health

hycamtin iv

novartis israel ltd - topotecan as hydrochloride - powder for solution for infusion - topotecan as hydrochloride 4 mg/vial - topotecan - topotecan - topotecan monotherapy is indicated for the treatment of:• patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.• patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with stage ivb disease.patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.